Clinical Trial

A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease

Study acronym: DOPAD-3
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated January 22, 2025 (before its estimated July 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a 24-week prospective, randomized, double-blind, placebo-controlled, multi-center phase III study evaluating efficacy and safety of rotigotine 4mg/24 hrs in combination with rivastigmine 9.5 mg/24 hrs in mild to moderate AD patients. The total study duration per patient from baseline to the end will be 24 weeks. The study has a placebo-controlled design to eliminate experimental biases that arise from a participants' expectations, observer's effect on the participants, observer bias, confirmation bias, and other sources.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-20.
Trial Details
NCT Number NCT06702124
Lead Sponsor I.R.C.C.S. Fondazione Santa Lucia
Conditions Alzheimer Disease
Enrollment 348 participants
Start Date 2023-12-01
Primary Completion 2025-07 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2025-01-22